Deficient MHC Class I and Adaptive Immune Response in Lung Cancer
DescriptionLung cancer is the most common cancer and a leading cause of cancer-related death worldwide. Immunotherapy is emerging as an important approach to treat lung cancer, however, effective only in a subset of lung cancer patients. We hypothesized that MHC Class I deficient tumors may be associated with resistance to immunotherapy due to their inability to present endogenous tumor neoantigens to cell surface for recognition by cytotoxic T lymphocytes. Thus, tumor MHC Class I gene mutation status could predict T cell clonal expansion and to further serve as a biomarker for checkpoint blockade therapy. Our objectives are: 1) to assess the association between the mutational status of genes involved in MHC Class I and T cell infiltration into the tumor area; 2) top validate the functional effects of mutant genes identified in the first Objective, 3) to evaluate in patient samples whether mutations in MHC class I genes could affect proliferation of CD8+T cell.
|Effective start/end date||1/09/16 → 21/01/19|